The inventors found that the conversion of serine at position 223 to asparagine (N223) in the HA protein of the H5N1 influenza virus increased the sensitivity of a hemagglutination inhibition (HI) assay in which this protein was used. This N223 change alters receptor specificity and/or antibody-antigen binding. The inclusion of the N223 residue in the HA proteins of diagnostic reference viruses may facilitate the evaluation of vaccine efficacy in humans.
Influenza, H5N1, hemagglutination inhibition assay
Granted Patents or Published Applications
US Patent No. 7,871,626; International Publication No. WO07/019094; European Publication No. 1924281.
Related Scientific References
Hoffmann E, Lipatov AS, Webby RJ, Govorkova EA, Webster RG., Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12915-20.
We are currently looking for licensees in fields other than veterinary use.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.